Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ARVN | PRESS-RELEASE | bearish | 8/10 | Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188.8M) and a GAAP EPS of -$0.90, significantly missing | May 12, 2026 |
| OVID | PRESS-RELEASE | mixed | 6/10 | Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) versus $10.2M loss a | May 12, 2026 |
| TENX | PRESS-RELEASE | neutral | 5/10 | Tenax Therapeutics reported Q1 2026 EPS of -$0.35, beating consensus of -$0.40 by 12.5%, but net loss widened to $15.7M | May 12, 2026 |
| ACHV | PRESS-RELEASE | mixed | 6/10 | Achieve Life Sciences reported Q1 2026 EPS of -$0.28, beating consensus of -$0.30 by 6.7%. The company also closed a $35 | May 12, 2026 |
| LEGN | PRESS-RELEASE | bullish | 7/10 | Legend Biotech reported Q1 2026 revenue of $305.1M (vs $306.5M consensus, slight miss) and EPS of -$0.15 (GAAP) vs conse | May 12, 2026 |
| SION | PRESS-RELEASE | neutral | 6/10 | Sionna reported Q1 2026 GAAP EPS of -$0.60, a 3.2% beat vs consensus of -$0.62, but net loss widened to $26.8M from $16. | May 12, 2026 |
| IMTX | PRESS-RELEASE | mixed | 6/10 | Immatics reported Q1 2026 EPS of -$0.29, a 33.9% beat vs consensus of -$0.44, but revenue fell sharply to $8.7M from $21 | May 12, 2026 |
| IRD | PRESS-RELEASE | bearish | 7/10 | Opus Genetics reported Q1 2026 EPS of -$0.75, a 212.5% miss vs consensus of -$0.14, driven by a $51.4M non-cash fair val | May 12, 2026 |
| OLMA | PRESS-RELEASE | neutral | 5/10 | Olema Oncology reported Q1 2026 EPS of -$0.52, a 7.2% beat vs consensus of -$0.54, but net loss widened to $53.1M from $ | May 12, 2026 |
| PRLD | PRESS-RELEASE | bullish | 7/10 | Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consensus of -$0.27, with revenue of $4.58M (vs $0 consensu | May 12, 2026 |
| CCCC | PRESS-RELEASE | mixed | 5/10 | C4 Therapeutics reported Q1 2026 results with an EPS beat ($-0.18 vs $-0.26 consensus) and revenue beat ($6.2M vs $4.4M | May 12, 2026 |
| ABOS | PRESS-RELEASE | neutral | 5/10 | Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowi | May 12, 2026 |
| MGNX | PRESS-RELEASE | mixed | 6/10 | MacroGenics is selling its GMP drug substance manufacturing operations to Bora Pharmaceuticals for a $122.5 million upfr | May 11, 2026 |
| BCDA | PRESS-RELEASE | neutral | 1/10 | BioCardia, Inc. announced it will host a conference call on May 15, 2026 to discuss its Q1 2026 results. | May 11, 2026 |
| BMEA | PRESS-RELEASE | neutral | 5/10 | Biomea Fusion reported Q1 2026 net loss of $12.4M ($0.17/share), significantly narrower than the $29.3M loss in Q1 2025, | May 11, 2026 |
| SCYX | PRESS-RELEASE | bearish | 7/10 | SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per share, significantly wider than the consensus estima | May 11, 2026 |
| CPRX | PRESS-RELEASE | bearish | 8/10 | Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, missing the consensus e | May 11, 2026 |
| PHVS | PRESS-RELEASE | neutral | 5/10 | Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' | May 11, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis reported Q1 2026 EPS of CHF -0.49 (vs consensus $-0.41), a miss of ~2.7% on a USD-converted basis. The company hi | May 11, 2026 |
| SANA | PRESS-RELEASE | bearish | 6/10 | Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but | May 11, 2026 |
| HROW | PRESS-RELEASE | mixed | 6/10 | Harrow reported Q1 2026 revenue of $44.2M, down 7.6% YoY from $47.8M, and a GAAP net loss per share of -$0.74, significa | May 11, 2026 |
| MGX | PRESS-RELEASE | bearish | 6/10 | Metagenomi reported Q1 2026 EPS of -$0.61, missing consensus of -$0.55 by 10.9%, and collaboration revenue of $1.25M, we | May 11, 2026 |
| KYNB | PRESS-RELEASE | mixed | 5/10 | Kyntra Bio reported Q1 2026 revenue of $3.7M (above $1.6M consensus) but EPS of -$3.74 missed the -$3.35 consensus by 11 | May 11, 2026 |
| PLRX | PRESS-RELEASE | bearish | 6/10 | Pliant Therapeutics reported Q1 2026 EPS of -$0.38, missing consensus of -$0.36 by 6.2%. Revenue was $0 (pre-revenue bio | May 11, 2026 |
| CHRS | PRESS-RELEASE | mixed | 6/10 | Coherus reported Q1 2026 GAAP EPS of -$0.27, beating consensus of -$0.29 by 6.9%, while revenue of $12.3M missed the $14 | May 11, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis reported Q1 2026 EPS of -$0.42, a 2.7% miss vs consensus of -$0.41, with no revenue. The miss is modest and the s | May 11, 2026 |
| CYTK | PRESS-RELEASE | neutral | 4/10 | Cytokinetics presented new data at ESC Heart Failure 2026 reinforcing the clinical profile of MYQORZO (aficamten) in obs | May 11, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio presented new acoramidis data at Heart Failure 2026, showing a 34% reduction in cardiovascular hospitalization | May 11, 2026 |
| FBLG | PRESS-RELEASE | neutral | 4/10 | FibroBiologics announced a strategic expansion of its fibroblast-based platform to target Hantavirus pulmonary syndrome | May 11, 2026 |
| FATE | PRESS-RELEASE | bullish | 7/10 | Fate Therapeutics presented clinical and preclinical data at ASGCT 2026 for its off-the-shelf iPSC-derived CAR T-cell pr | May 11, 2026 |